…
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets synthetic, biological, and biorational products for agricultural, commercial, and consumer uses in the United States and internationally. The company synthesizes and formulates chemicals and ferments and extracts microbial products for crops, turf, ornamental plants, and human and animal health protection, such as insecticides, fungicides, herbicides, soil health, plant nutrition, molluscicides, growth regulators, soil fumigants, and biorationals in liquid, powder, and granular forms. It distributes its products through national distribution companies, buying groups, or co-operatives, as well as through sales offices, wholly owned distributors, sales force executives, and sales agents. American Vanguard Corporation was incorporated in 1969 and is headquartered in Newport Beach, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
American Vanguard Corporation manufactures and sells crop protection and specialty chemical products for agricultural, professional pest control and consumer markets, supplying formulated insecticides, herbicides and related solutions across multiple geographies. Long-term growth may be driven by steady demand for crop protection, geographic expansion and new product approvals or formulations, and investors may find the company attractive for its diversified product mix and exposure to recurring agricultural spending.
Material risks include regulatory and litigation exposure tied to pesticide approvals and product safety, competitive pressures and pricing, raw-material cost volatility and sensitivity to agricultural cycles and foreign-market fluctuations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -47.20M | -120.46M | 10.30M | 35.97M | 27.14M |
| Net income | -49.88M | -126.34M | 7.52M | 27.40M | 18.59M |
| Selling general administrative | 98.51M | 115.52M | 111.15M | 53.46M | 61.69M |
| Selling and marketing expenses | - | 4.11M | 5.74M | 101.48M | 91.93M |
| Gross profit | 135.44M | 120.32M | 179.16M | 241.35M | 213.24M |
| Reconciled depreciation | 18.74M | 22.32M | 21.89M | 22.14M | 22.23M |
| Ebit | 6.58M | -31.98M | 22.94M | 40.65M | 30.95M |
| Ebitda | 25.32M | -9.43M | 44.72M | 62.79M | 53.68M |
| Depreciation and amortization | 18.74M | 22.55M | 21.78M | 22.14M | 22.73M |
| Operating income | 6.58M | -101.56M | 23.30M | 40.65M | 30.95M |
| Other operating expenses | 508.53M | 648.86M | 556.08M | 568.96M | 526.10M |
| Interest expense | 18.58M | 16.78M | 12.64M | 3.95M | 3.69M |
| Tax provision | 2.68M | 5.88M | 0.44M | 8.56M | 8.17M |
| Interest income | 0.11M | 18.90M | 0.37M | 4.69M | 4.48M |
| Net interest income | -18.47M | -16.55M | -9.98M | -3.95M | -3.69M |
| Income tax expense | 2.68M | 5.88M | 2.78M | 8.56M | 8.17M |
| Total revenue | 515.11M | 547.31M | 579.37M | 609.62M | 556.87M |
| Total operating expenses | 128.86M | 221.87M | 155.87M | 200.70M | 182.47M |
| Cost of revenue | 379.68M | 426.99M | 400.21M | 368.26M | 343.63M |
| Total other income expense net | -53.78M | -18.90M | -13.00M | -4.69M | -3.81M |
| Net income from continuing ops | -49.88M | -126.34M | 4.44M | 27.40M | 18.98M |
| Net income applicable to common shares | -49.88M | -126.34M | 7.52M | 27.40M | 18.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 596.54M | 636.72M | 767.55M | 726.31M | 694.16M |
| Intangible assets | 138.75M | 150.50M | 172.51M | 184.66M | 197.84M |
| Other current assets | 14.27M | 7.62M | 6.26M | 15.85M | 12.49M |
| Total liab | 404.14M | 403.61M | 397.54M | 356.33M | 321.42M |
| Total stockholder equity | 192.40M | 233.11M | 370.01M | 369.98M | 372.74M |
| Deferred long term liab | - | - | - | 14.60M | 20.01M |
| Other current liab | 113.58M | 101.44M | 84.43M | 81.72M | 87.80M |
| Common stock | 3.49M | 3.48M | 3.47M | 3.44M | 3.43M |
| Capital stock | 3.49M | 3.48M | 3.47M | 3.44M | 3.43M |
| Retained earnings | 155.00M | 204.88M | 332.90M | 328.75M | 304.38M |
| Other liab | - | - | - | 18.76M | 25.34M |
| Good will | 0.00M | 19.70M | 51.20M | 47.01M | 46.26M |
| Other assets | 17.44M | 9.73M | 0.00M | 10.91M | 28.78M |
| Cash | 12.43M | 12.51M | 11.42M | 20.33M | 16.29M |
| Cash and equivalents | 12.43M | 12.51M | 11.42M | 20.33M | 16.29M |
| Total current liabilities | 209.45M | 232.35M | 230.50M | 266.60M | 223.06M |
| Current deferred revenue | - | 52.67M | 65.56M | 110.60M | 63.06M |
| Net debt | 178.96M | 155.29M | 150.68M | 55.92M | 61.79M |
| Short term debt | 5.76M | 6.14M | 6.08M | 5.28M | 5.06M |
| Short long term debt total | 191.39M | 167.81M | 162.09M | 76.25M | 78.08M |
| Other stockholder equity | 45.91M | 43.48M | 39.61M | 49.97M | 78.71M |
| Property plant equipment | 69.83M | 77.90M | 96.98M | 70.91M | 91.50M |
| Total current assets | 370.52M | 378.89M | 432.02M | 388.57M | 342.00M |
| Net tangible assets | - | - | - | 138.31M | 128.64M |
| Short term investments | - | - | -0.42M | - | - |
| Net receivables | 167.79M | 179.47M | 194.79M | 168.20M | 158.92M |
| Long term debt | 174.00M | 147.33M | 138.90M | 51.48M | 52.24M |
| Inventory | 176.03M | 179.29M | 219.55M | 184.19M | 154.31M |
| Accounts payable | 87.50M | 69.16M | 68.83M | 69.00M | 67.14M |
| Accumulated other comprehensive income | -12.00M | -18.73M | -5.96M | -12.18M | -13.78M |
| Common stock total equity | - | - | - | 3.44M | 3.43M |
| Retained earnings total equity | - | - | - | 328.75M | 304.38M |
| Treasury stock | - | - | - | -55.66M | -22.74M |
| Non currrent assets other | 14.80M | 8.48M | 14.84M | 10.77M | 16.29M |
| Non current assets total | 226.01M | 257.83M | 335.53M | 337.75M | 352.16M |
| Capital lease obligations | 17.39M | 20.48M | 23.19M | 24.77M | 25.84M |
| Long term debt total | 174.00M | 147.33M | 138.90M | 51.48M | 52.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -6.62M | -13.64M | -14.47M | -20.04M |
| Change to liabilities | - | - | - | -5.57M | 36.70M |
| Total cashflows from investing activities | -6.62M | -6.62M | -17.02M | -14.47M | -20.04M |
| Net borrowings | 26.67M | 8.43M | 86.60M | -1.00M | -55.57M |
| Total cash from financing activities | 4.54M | 4.54M | 66.74M | -38.26M | -65.87M |
| Change to operating activities | - | - | - | -6.76M | 18.80M |
| Net income | -126.34M | -126.34M | 7.52M | 27.40M | 18.59M |
| Change in cash | 1.10M | 1.10M | -8.91M | 4.04M | 0.36M |
| Begin period cash flow | 11.42M | 11.42M | 20.33M | 16.29M | 15.92M |
| End period cash flow | 12.51M | 12.51M | 11.42M | 20.33M | 16.29M |
| Total cash from operating activities | 3.92M | 3.92M | -58.75M | 57.10M | 87.32M |
| Issuance of capital stock | - | - | - | - | 0.74M |
| Depreciation | 22.55M | 22.32M | 21.78M | 22.14M | 22.23M |
| Other cashflows from investing activities | 0.66M | 1.06M | 0.24M | -1.21M | -10.00M |
| Dividends paid | 2.51M | 2.51M | 3.38M | -2.79M | -2.38M |
| Change to inventory | 6.29M | 35.18M | -27.32M | -29.56M | 8.13M |
| Change to account receivables | 7.69M | 3.71M | -16.71M | -6.45M | -24.35M |
| Sale purchase of stock | -1.43M | -1.43M | -17.51M | -36.07M | -7.53M |
| Other cashflows from financing activities | -16.65M | 0.05M | 1.03M | 254.60M | -1.13M |
| Change to netincome | - | - | - | 2.43M | 6.22M |
| Capital expenditures | 7.28M | 7.69M | 12.06M | 14.55M | 10.04M |
| Change receivables | - | - | - | -6.45M | -24.35M |
| Cash flows other operating | - | - | - | 46.42M | 18.48M |
| Cash and cash equivalents changes | - | - | - | 4.38M | 0.45M |
| Change in working capital | -20.22M | 48.01M | -87.94M | 2.96M | 36.69M |
| Stock based compensation | 4.41M | 4.41M | 6.14M | 5.68M | 6.88M |
| Other non cash items | 122.07M | 55.62M | 3.98M | 5.63M | 5.85M |
| Free cash flow | -3.36M | -3.77M | -70.81M | 42.55M | 77.28M |
Sector: Basic Materials Industry: Agricultural Inputs
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AVD American Vanguard Corporation |
0.01 0.62% |
0.97 | - | 15.08 | 0.13 | 0.36 | 0.60 | 10.49 |
| CTA-PB E. I. du Pont de Nemours and Company |
- -% |
56.50 | - | - | 3.43 | - | - | - |
| CTVA Corteva Inc |
0.10 0.80% |
11.99 | 49.93 | 19.65 | 3.12 | 2.19 | 3.23 | 19.19 |
| CTA-PA E. I. du Pont de Nemours and Company |
-0.96 2.08% |
45.04 | - | - | 2.71 | - | - | - |
| NTR Nutrien Ltd |
0.64 0.90% |
72.12 | 15.94 | 14.90 | 1.38 | 1.42 | 1.72 | 7.72 |
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets synthetic, biological, and biorational products for agricultural, commercial, and consumer uses in the United States and internationally. The company synthesizes and formulates chemicals and ferments and extracts microbial products for crops, turf, ornamental plants, and human and animal health protection, such as insecticides, fungicides, herbicides, soil health, plant nutrition, molluscicides, growth regulators, soil fumigants, and biorationals in liquid, powder, and granular forms. It distributes its products through national distribution companies, buying groups, or co-operatives, as well as through sales offices, wholly owned distributors, sales force executives, and sales agents. American Vanguard Corporation was incorporated in 1969 and is headquartered in Newport Beach, California.
4695 MacArthur Court, Newport Beach, CA, United States, 92660
949 260 1200
739
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric G. Wintemute | Chairman & CEO | 1956 |
| Mr. David T. Johnson | VP, CFO & Treasurer | 1957 |
| Dr. Ulrich G. Trogele Ph.D. | COO & Exec. VP | 1958 |
| Mr. Timothy J. Donnelly Esq. | Gen. Counsel, Chief Admin. Officer & Sec. | 1960 |
| Mr. Peter E. Eilers | Managing Director of AMVAC Netherlands BV | 1964 |
| Mr. Anthony Scott Hendrix | Sr. VP of Crop Sales for U.S. & Canada | 1971 |
| Mr. William A. Kuser | Director of Investor Relations & Corp. Communications | NA |
| Mr. Robert F. Gilbane | Pres of Gemchem Inc | 1951 |
| James Thompson | Director of Bus. Devel., Portfolio Management Biologicals & Non-Crop | NA |
| Mr. Douglas A. Kaye III | Chairman & CEO | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.